
Opinion|Videos|January 7, 2025
SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety
Panelists discuss how afamitresgene autoleucel (afami-cel) demonstrated meaningful clinical activity in SPEARHEAD-1, with manageable cytokine release syndrome as the main safety concern.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Briefly review the pivotal SPEARHEAD-1 trial that led to afami-cel’s approval.
- Please review study design, key efficacy and safety (
Tine et al, CTOS2022 ). - Please explain the role of targeting MAGE-A4.
Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5

